Assuntos
Agranulocitose/tratamento farmacológico , Lítio/uso terapêutico , Neutrófilos/fisiologia , Fosfatase Ácida/sangue , Adolescente , Adulto , Idoso , Agranulocitose/enzimologia , Fosfatase Alcalina/sangue , Glucuronidase/sangue , Humanos , Carbonato de Lítio , Pessoa de Meia-Idade , Neutrófilos/enzimologia , Peroxidase/sangue , FagocitoseAssuntos
Agranulocitose/sangue , Lítio/uso terapêutico , Neutrófilos/fisiologia , Fosfatase Ácida/sangue , Adolescente , Adulto , Idoso , Agranulocitose/tratamento farmacológico , Fosfatase Alcalina/sangue , Glucuronidase/sangue , Humanos , Técnicas In Vitro , Pessoa de Meia-Idade , Neutrófilos/enzimologia , Peroxidase/sangue , FagocitoseRESUMO
Administration of lithium carbonate, 750 mg daily, during 10 days to 25 patients with essential granulocytopenia, induced an increase of the total leukocyte count, of the absolute count of neutrophils and of the number of neutrophils phagocytizing Staphylococcus aureus Oxford in vitro. An enhancement of acid phosphatase activity in the neutrophils was noted both in the patients and the healthy subjects in the control group. In the patients, the counts of neutrophils exhibiting a positive enzymatic reaction with regard to beta-glucuronidase, myeloperoxidase and alkaline phosphatase were also increased after treatment with lithium carbonate. Based on these results, the authors recommend the clinical application of this treatment in patients with granulocytopenia.